ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock Feb 6, 2020
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook Jan 9, 2020
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions Jan 7, 2020
ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress Nov 6, 2019
